Oligosaccharide as therapeutic agent for alcohol associated liver disease
AssigneeThe Regents of the University of California
InventorsLars Bode, Bernd Schnabl
Life of this patent
Estimating the term…
Abstract
The disclosure provides for the use of an oligosaccharide for the treatment of liver disease. More particularly, the disclosure provide methods and composition for treating liver disease comprising administering 2′-FL to a subject.
Claims19
A method for treating a subject with alcohol induced liver disease, comprising administering to the subject an effective amount of a composition comprising an oligosaccharide with a structure of Formula I:
- or a pharmaceutically acceptable salt, polymorph, solvate, or prodrug thereof, wherein:
- R1-R20 are independently selected from the group consisting of H, D, halo, azide, nitro, amine, aldehyde, alkoxy, ketone, ester, carboxylic acid, hydroxyl, substituted or non-substituted (C1-C6)alkyl, substituted or non-substituted (C1-C6)heteroalkyl, substituted or non-substituted (C2-C6)alkenyl, substituted or non-substituted (C2-C6)heteroalkenyl, optionally substituted or non-substituted (C2-C6)alkynyl, substituted or non-substituted (C2-C6)heteroalkynyl, and heterocycle;
- and wherein the effective amount is obtained to inhibit fecal Enterococcus faecalis and/or cytolysin in the presence of alcohol.
A method to restore or compensate for the loss α1-2-fucosylated glycans on the surface of a subject's intestinal epithelial cells caused by excessive and/or chronic alcohol consumption, comprising:
- administering to the subject an effective amount of an oligosaccharide of Formula I, or a composition comprising an effective amount of an oligosaccharide of Formula I:
- or a pharmaceutically acceptable salt, polymorph, solvate, or prodrug thereof, wherein:
- R1-R20 are independently selected from the group consisting of H, D, halo, azide, nitro, amine, aldehyde, alkoxy, ketone, ester, carboxylic acid, hydroxyl, substituted or non-substituted (C1-C6)alkyl, substituted or non-substituted (C1-C6)heteroalkyl, substituted or non-substituted (C2-C6)alkenyl, substituted or non-substituted (C2-C6)heteroalkenyl, substituted or non-substituted (C2-C6)alkynyl, substituted or non-substituted (C2-C6)heteroalkynyl, and heterocycle;
- and wherein the effective amount is obtained to inhibit fecal Enterococcus faecalis and/or cytolysin in the presence of alcohol.
Dependencies are inferred from the claim text.